

Rheumatoid Arthritis

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02608112 ML29256

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT02608112 ML29256
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years

Healthy Volunteers
No
